Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025
Coptisine activates aryl hydrocarbon receptor to regulate colonic epithelial homeostasis in DSS induced ulcerative colitis and TNF-α challenged intestinal organoids.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tan Bingyan, Zhang Jingyan, Kang An, Zhang Li, Fang Dan, Wu Hong, Han Tai, Qiu Rongli, Li Hui, Sun Dongdong
Аннотация
BACKGROUND: Coptisine is a bioactive isoquinoline alkaloid derived from Coptis Chinensis, exhibiting significant pharmacological potential. Emerging evidence suggests its therapeutic efficacy in gastrointestinal disorders through modulating inflammation and maintaining gut homeostasis.
PURPOSE: The study aimed to elucidate the molecular mechanisms underlying coptisine mediated restoration of intestinal barrier integrity in ulcerative colitis (UC) and TNF-α challenged intestinal organoids.
METHODS: A murine UC model was established by dextran sulfate sodium (DSS) induction to evaluate coptisine's therapeutic effects on colonic inflammation and mucosal barrier dysfunction. Complementary in vitro investigations were conducted using TNF-α-challenged HT-29 cells and intestinal organoids derived from wild-type mice to assess epithelial barrier repair capabilities. Additionally, we utilized an integrated experimental approach incorporating cellular thermal shift assay, luciferase reporter assays to explore the influence of coptisine on AhR activation. Lastly, specific AhR dependency of coptisine on barrier protective effects were further validated through three independent model systems: shAhR-transfected HT-29 cells, AhR KO murine intestinal organoids, and AhR KO mice subjected to DSS challenge.
RESULTS: Coptisine administration significantly attenuated colitis severity in DSS-treated mice, evidenced by reduced histopathological scores, decreased colonic inflammation, and enhanced gut barrier integrity through upregulation of tight junction proteins (TJ proteins). In a barrier dysfunction model of TNF-α stimulation in HT-29 cells and intestinal organoids, coptisine treatment effectively normalized the expression levels of TJ proteins. Mechanistically, coptisine exhibited potent AhR activation through increased nuclear translocation and transcriptional regulation of CYP1A1. Coptisine dose-dependently inhibited reactive oxygen species (ROS) production and NF-κB activation in TNF-α treated HT-29 cells. Crucially, AhR knockdown or knockout completely abolished coptisine's inhibitory effects on NF-κB activation and the protective efficacy in barrier function, confirming pathway dependency.
CONCLUSION: Coptisine ameliorates intestinal barrier dysfunction and improves UC related symptom in an AhR-dependent manner. This mechanistic insight positions coptisine as a promising phytochemical candidate for UC therapy.
PURPOSE: The study aimed to elucidate the molecular mechanisms underlying coptisine mediated restoration of intestinal barrier integrity in ulcerative colitis (UC) and TNF-α challenged intestinal organoids.
METHODS: A murine UC model was established by dextran sulfate sodium (DSS) induction to evaluate coptisine's therapeutic effects on colonic inflammation and mucosal barrier dysfunction. Complementary in vitro investigations were conducted using TNF-α-challenged HT-29 cells and intestinal organoids derived from wild-type mice to assess epithelial barrier repair capabilities. Additionally, we utilized an integrated experimental approach incorporating cellular thermal shift assay, luciferase reporter assays to explore the influence of coptisine on AhR activation. Lastly, specific AhR dependency of coptisine on barrier protective effects were further validated through three independent model systems: shAhR-transfected HT-29 cells, AhR KO murine intestinal organoids, and AhR KO mice subjected to DSS challenge.
RESULTS: Coptisine administration significantly attenuated colitis severity in DSS-treated mice, evidenced by reduced histopathological scores, decreased colonic inflammation, and enhanced gut barrier integrity through upregulation of tight junction proteins (TJ proteins). In a barrier dysfunction model of TNF-α stimulation in HT-29 cells and intestinal organoids, coptisine treatment effectively normalized the expression levels of TJ proteins. Mechanistically, coptisine exhibited potent AhR activation through increased nuclear translocation and transcriptional regulation of CYP1A1. Coptisine dose-dependently inhibited reactive oxygen species (ROS) production and NF-κB activation in TNF-α treated HT-29 cells. Crucially, AhR knockdown or knockout completely abolished coptisine's inhibitory effects on NF-κB activation and the protective efficacy in barrier function, confirming pathway dependency.
CONCLUSION: Coptisine ameliorates intestinal barrier dysfunction and improves UC related symptom in an AhR-dependent manner. This mechanistic insight positions coptisine as a promising phytochemical candidate for UC therapy.